NCT05988047Completed
Analysis of CMTM6 Expression in Patients With Acute Myeloid Leukemia
Source: ClinicalTrials.gov · Last updated 8 May 2024
Brief summary (registry, in English)
In this study, we aim to investigate the expression of CKLF like MARVEL transmembrane domain containing 6 (CMTM6) in leukemia cells of patients with acute myeloid leukemia (AML). We will use peripheral blood samples and assess CMTM6 expression by flow cytometry and Western Blot.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 150 (actual)
- First submitted
- 4 Aug 2023
- Start date
- 1 May 2020
- Primary completion date
- 1 May 2024
- Lead sponsor
- University of Freiburg
- Diseases
- Acute myeloid leukemia
- NCT number
- NCT05988047
What you commit to
- Study type: Observational
- Participants enrolled: 150
- From 1 May 2020 to the primary completion date, 1 May 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Age
- age \< 18 years
Other
- lack of informed consent
Who the study is looking for
- age ≥ 18 years
- primary diagnosis of acute myeloid leukemia
- diagnosis results available
- written informed consent
- ability to understand the nature of the study and the study related procedures and to comply with them
Age in the registry: 18 years to 99 years · Sex: All
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Medical Center- University of Freiburg Coordinator of this site? Confirm its status | Freiburg im Breisgau | Germany | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.